Patient dosage and usage of the anti-tuberculosis drug bedaquiline

Bedaquiline (Bedaquiline) is a new anti-tuberculosis drug for the treatment of multidrug-resistant tuberculosis (MDR-TB) and is one of the important drugs in the treatment of tuberculosis. It kills bacteria by inhibiting the ATP synthase of Mycobacterium tuberculosis and reducing the production of bacterial energy. Bedaquiline is generally used as part of multidrug combination therapy, particularly in patients who are resistant to conventional antituberculosis drugs. Below are dosage and instructions for bedaquiline.

1. Routine dosage for adult patients

In adults, bedaquiline is usually used in combination with other antituberculosis drugs. According to international standard treatment protocols, the standard dosage of bedaquiline is as follows:

Initial treatment phase (first two months): Oral administration 1 times a day, 400mg each time (i.e. 2 tablets 100mg). This stage of treatment usually lasts for 2 months and is mainly used to remove a large number of Mycobacterium tuberculosis from the body and reduce the burden of the bacteria.

Maintenance treatment phase (next 4 months): Oral administration 1 times a day, 200mg each time (i.e. 1 tablets100mg). The medication time at this stage is 4 months. The purpose is to consolidate the treatment effect, prevent the emergence of drug-resistant bacteria and further kill remaining bacteria.

2. How to take medicine

Bedaquiline is an oral medication, usually available in tablet form. Patients should follow the dosage and frequency of administration exactly as directed by their doctor. It is recommended to take it after meals to reduce gastrointestinal discomfort. At the same time, patients need to avoid missing doses or increasing the dose at will. If they miss a dose, they should take it as early as possible on the same day, but do not add twice the dose at once when taking the next dose.

3. Treatment duration

Bedaquiline is usually used during treatment for 6 months. A higher dose is used in the initial phase to inhibit bacterial growth as early as possible, while a lower dose is used in the maintenance phase to reduce side effects. The entire treatment cycle is 6 months, of which the first two months are high-dose treatment and the last four months are low-dose treatment. Depending on the patient's specific conditions, the treatment cycle may be adjusted, but it is not recommended to stop medication or interrupt treatment on your own.

4. Dose adjustment in special circumstances

In patients with hepatic insufficiency or renal impairment, the dose of bedaquiline may need to be adjusted appropriately. Since the metabolism of the drug is mainly carried out by the liver, patients need to undergo regular liver function tests during use. In addition, if patients experience serious adverse reactions or complications, treatment plans may need to be adjusted on a case-by-case basis.

5. Combined use with other drugs

Bedaquiline is often used in combination with other anti-tuberculosis drugs, such as rifampicin, isoniazid, cyclazotomycin, etc., to achieve better efficacy. Combination therapy can reduce the occurrence of drug-resistant strains and improve the success rate of treatment. Patients need to work closely with their doctors during medication and follow the recommended combination medication regimen.

6. Adverse reactions and monitoring

Bedaquiline may cause some adverse reactions, including but not limited to cardiotoxicity, liver damage, nausea, headache, joint pain, etc. Patients need to regularly check electrocardiogram (ECG), liver function and other indicators during medication to ensure the safety of medication. If serious adverse reactions occur, you should seek medical treatment promptly and adjust the treatment plan according to the doctor's advice.

7. Discontinuing and changing medications

If the patient develops obvious intolerance or drug inefficiency during treatment, the drug may need to be discontinued or other treatment options need to be changed. During the use of bedaquiline, patients should strictly follow the doctor's instructions and never stop or adjust the dosage of the drug on their own to avoid affecting the therapeutic effect.

8.Management of long-term treatment

Bedaquiline should not be used in isolation but as part of a multidrug regimen. The treatment process may last half a year or more. Patients need to maintain close contact with their doctors, review their condition regularly, and adjust their medication regimen to ensure maximum treatment effects.

Bedaquiline, as an important drug in the treatment of multidrug-resistant tuberculosis, has significant efficacy and good drug resistance inhibition. Patients should strictly follow medical instructions, take medications on time, and conduct necessary monitoring. With combination therapy and judicious use, bedaquiline can help patients effectively treat TB, especially those with drug-resistant TB.